Methylene blue photodynamic therapy for treatment of common warts

Photodynamic immune modulation in common warts: the impact of methylene blue therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202607875594537

Enrollment

Registered

2026-07-06

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases Common warts caused by human papillomavirus infection

Interventions

Methylene Blue Photodynamic Therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of both sexes aged 18 years or older Presence of multiple clinically diagnosed common warts No topical, systemic, or procedural wart treatment within the preceding month Ability and willingness to provide informed consent

Exclusion criteria

Exclusion criteria: Known hypersensitivity to methylene blue History of photosensitivity or diagnosed photodermatoses Pregnancy or lactation Severe autoimmune disease Uncontrolled diabetes mellitus Current or recent use of systemic corticosteroids or immunosuppressive therapy within the previous month

Design outcomes

Primary

Measure	Time frame
Percentage reduction in the size of treated common warts after methylene blue photodynamic therapy	—

Secondary

Measure	Time frame
Change in serum IL-2 and TNF-alpha levels following methylene blue photodynamic therapy	—

Countries

Egypt

Contacts

Public ContactFatma Elkoumy

Department of Dermatology and Venereology Faculty of Medicine for Girls AlAzhar University

Fatmaelkomy@azhar.edu.eg+201157518751

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026